ERBB2 and breast cancer: This study retrospectively investigated the efficacy and safety of pyrotinib-based regimens for the treatment of patients with HER2-positive stage III/IV BC in practical clinical applications and analyzed the efficacy of pyrotinib-based regimens in different subgroups.